Epidarex Capital secures £109M first close for early-stage life sciences fund
What’s the deal? Edinburgh-based Epidarex Capital has secured a first close of £109 million for its fourth fund to back early-stage life sciences startups. The fund will focus on pre-seed and seed investments in drug discovery and related technologies across the UK, Europe, and the US.
Epidarex typically writes cheques of £500,000 to £1.5 million and targets companies emerging from academic research. The fund builds on its long-standing strategy of backing science-led startups at formation.
Why now? The raise comes as early-stage biotech funding remains constrained, particularly for first-time founders spinning out of universities. Epidarex is positioning itself to fill that gap as larger funds move downstream and public markets stay volatile.
The fund has backing from institutional investors including the British Business Bank and the Scottish National Investment BankDealroom has a profile for this one. Try Dealroom →, which committed £15 million, underscoring public support for domestic life sciences innovation.
What could go wrong? Early-stage life sciences investing carries high technical and regulatory risk, with long timelines before clinical or commercial proof. A weaker exit environment could also delay returns, especially for drug discovery companies reliant on acquisitions by larger pharma groups.
Concentrating on very early-stage projects means Epidarex must rely heavily on scientific judgment and follow-on capital from later-stage investors.
The signal: The fund highlights continued confidence in Europe’s life sciences pipeline despite tighter venture markets. Specialist funds with deep scientific focus are still able to raise capital when they target clear gaps in the ecosystem.
It also reflects a broader push by public and private investors to support early innovation, aiming to keep promising biomedical research from stalling before it reaches scale.
Sources:
Epidarex Capital
Scottish National Investment Bank
European Biotechnology
The Next Leap
PE Insights
FirstWord Pharma
J.V.
